| Metric | This Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥47.6B | ¥42.3B | +12.6% |
| Operating Income / Operating Profit | ¥-11.4B | ¥-13.7B | +16.6% |
| Profit Before Tax | ¥-12.0B | ¥-14.3B | +16.1% |
| Net Income / Net Profit | ¥-8.5B | ¥-10.3B | +17.3% |
| ROE | -1.7% | -2.0% | - |
FY2026 Q1 results: Revenue ¥47.6B (YoY +¥5.3B +12.6%), operating loss ¥11.4B (YoY improved by ¥2.3B, loss narrowed by 16.6%), ordinary loss ¥12.2B (YoY improved by ¥2.3B, loss narrowed by 16.1%), net loss ¥8.5B (YoY improved by ¥1.8B, loss narrowed by 17.3%). The Radiopharmaceuticals Business accounted for 85.9% of revenue and drove a YoY increase of +7.0%, while the Drug Discovery & Development Business recovered sharply with +64.6%. Gross margin improved materially to 42.6% (from 34.7% a year earlier, +7.9pp) as manufacturing efficiency and product mix improved. R&D expenses remained heavy at ¥12.3B (25.8% of revenue), and operating losses continued. Net loss was mitigated by tax benefits of ¥3.5B, showing improvement YoY. Cash balance ¥255.5B, interest-bearing debt ¥163.4B, resulting in net cash approx. ¥92B. Short-term borrowings were significantly reduced from ¥170.4B to ¥26.1B with refinancing into long-term borrowings of ¥137.3B, improving financial stability. Operating Cash Flow was negative ¥9.5B but markedly improved from ¥-98.3B a year earlier. Against full-year plan (Revenue ¥320.0B, Operating Income ¥46.0B), Q1 progress is weak at 14.9% of revenue; recognition of milestones from Q2 onward and segment margin improvements will be key to achieving targets.
[Revenue] Revenue was ¥47.6B, up ¥5.3B YoY (+12.6%). Core Radiopharmaceuticals Business external sales were ¥40.9B (prior year ¥38.3B, +7.0%), accounting for 85.9% of total revenue, supported by expanding diagnostic and therapeutic radiopharmaceutical demand and scale effects. Drug Discovery & Development external sales surged to ¥6.7B (prior year ¥4.1B, +64.6%), driven by technology licensing and progress in co-development agreements. Including inter-segment sales, Radiopharmaceuticals totaled ¥43.4B (prior year ¥40.1B) and Drug Discovery & Development ¥6.7B (prior year ¥4.1B). Although regional/product breakdown is not disclosed in detail, company-wide 12.6% growth is estimated to reflect both diagnostic demand and progress in discovery partnerships.
[Profitability] Cost of sales was ¥27.4B (prior year ¥27.6B), nearly flat, and gross profit jumped to ¥20.3B (prior year ¥14.7B, +38.1%), with gross margin improving to 42.6% (from 34.7%, +7.9pp). Manufacturing efficiency and product mix improvements boosted gross margin. SG&A was ¥19.3B (prior year ¥18.4B, +4.6%), and R&D was ¥12.3B (prior year ¥9.9B, +24.6%), reflecting front-loaded investment in drug discovery. Operating loss was ¥11.4B (prior year ¥13.7B), narrowing by ¥2.3B as gross margin improvement absorbed higher expenses. Financial income ¥0.9B and financial expenses ¥1.6B produced net financial expense of ¥-0.6B (almost unchanged from prior year ¥-0.6B). Equity-method loss ¥0.0B added to ordinary loss of ¥12.2B (prior year ¥14.3B). Other income/expenses were net ¥-0.1B and extraordinary items were negligible, resulting in loss before tax of ¥12.0B (prior year ¥14.3B). Income tax benefit was ¥3.5B (prior year ¥4.0B benefit), aided by restrained derecognition of deferred tax assets, leading to net loss of ¥8.5B (prior year ¥10.3B). In summary, this quarter was characterized by revenue growth and reduced losses (narrowing of deficits), with an ongoing tug-of-war between gross margin improvement and front-loaded expenditure.
Radiopharmaceuticals Business: Revenue ¥40.9B (prior year ¥38.3B, +7.0%), operating income ¥0.7B (prior year ¥0.8B, -10.7%) implying a margin of 1.8%. Demand for diagnostic and therapeutic radiopharmaceuticals is healthy, but extremely thin margins indicate a heavy cost structure. Including inter-segment sales, total for the segment was ¥43.4B (prior year ¥40.1B), reflecting expanded intra-group supply and higher manufacturing capacity utilization, though fixed-cost absorption remains limited. Drug Discovery & Development: Revenue ¥6.7B (prior year ¥4.1B, +64.6%), but operating loss ¥11.9B (prior year ¥14.3B), loss narrowed by 16.5%, with a margin of -177.9%, indicating severe losses. The burden of front-loaded R&D spending is significant; milestone and license revenue timing creates high volatility. Adjustment items include business combination related expenses (amortization of intangible assets) ¥0.2B, leaving consolidated operating loss at ¥11.4B. Improvement in Radiopharmaceuticals margins and turning Drug Discovery & Development to profitability are essential for consolidated profitability improvements.
[Profitability] Operating margin was -23.9% (prior year -32.3%), narrowing but still severe. Gross margin improved materially to 42.6% (from 34.7%, +7.9pp), reflecting manufacturing efficiency and a shift to higher value-added products. SG&A ratio was 40.5% (prior year 43.6%), R&D ratio 25.8% (prior year 23.3%), indicating R&D front-loading. ROE was -1.7% (prior year -2.0%), improving but negative. Net profit margin -17.9% (prior year -24.4%) × Total Asset Turnover 0.064 (prior year 0.055) × Financial Leverage 1.50 (prior year 1.49): improvement was mainly driven by net profit margin. EBITDA approximated: operating loss ¥-11.4B + depreciation and amortization ¥5.4B = approx. ¥-6.0B, yielding EBITDA margin of about -12.6%. [Cash Quality] Operating CF ¥-9.5B is roughly in line with net loss ¥-8.5B, indicating cash generation remains weak. This is a major improvement from ¥-98.3B a year earlier, but inventory increase ¥-4.4B and other outflows ¥-11.8B weighed on cash. Operating CF / Net Income is negative for both, making formal ratio interpretation difficult, but YoY improvement is substantial. Working capital management saw accounts receivable decrease +¥9.3B (positive), inventory increase -¥4.4B and prepaid expenses/others -¥11.8B (negative). [Investment Efficiency] ROA was -1.1% (prior year -1.3%), improving though negative. ROIC is not computable (negative operating income), but with business assets ~¥600B and operating loss ¥-11.4B, this equates to about -1.9%, suggesting fundamental capital efficiency improvements require a return to profitability. Total asset turnover was 0.064x (prior year 0.055x), mildly improved; composition of cash, goodwill and fixed assets depresses turnover. [Financial Soundness] Equity ratio 66.6% (prior year 66.9%) remains high and stable. Interest-bearing debt ¥163.4B (short-term borrowings ¥26.1B + long-term borrowings ¥137.3B), cash ¥255.5B, net cash approx. ¥92B, net D/E -0.18x, effectively near zero net debt. Current ratio 406% (prior year 166%) markedly improved due to conversion of short-term borrowings to long-term. Goodwill ¥83.7B (16.8% of shareholders' equity) is moderate and impairment risk is manageable.
Operating CF was ¥-9.5B (prior year ¥-98.3B), a major improvement from last year's large negative but still negative. Starting from pre-tax quarterly loss ¥-12.0B plus depreciation/amortization ¥5.4B, working capital contributed with decrease in trade receivables +¥9.3B (inflow), inventory increase -¥4.4B, retirement benefit -¥0.0B, and other items -¥11.8B (outflow). Large other outflows were mainly uncollected corporate income taxes ¥-3.9B and decrease in contract liabilities ¥-2.5B; adjustments to advance receipts and prepaid items pressured cash flow. Interest received ¥0.5B, interest paid ¥-0.9B, corporate tax paid ¥-0.0B resulted in operating CF ¥-9.5B. Investing CF was ¥-3.2B, including acquisition of tangible fixed assets ¥-2.7B, acquisition of intangible assets ¥-0.6B, loan recovery +¥0.0B, and others +¥0.2B. Free CF was approx. ¥-12.7B (operating CF -¥9.5B + investing CF -¥3.2B), indicating ongoing outflow. Financing CF was ¥-19.0B, with long-term borrowings +¥164.4B, repayment of long-term borrowings -¥171.0B, installment payments -¥0.5B, borrowing fees -¥1.0B, lease repayments -¥0.9B, and treasury stock acquisition -¥10.0B as principal items. Short-term borrowings reduced substantially from ¥170.4B to ¥26.1B (decrease ¥144.3B), and long-term borrowings increased from 0 to ¥137.3B; net decrease due to refinancing and repayment was approx. ¥16.0B. Foreign exchange effects +¥0.3B; cash and equivalents from opening ¥286.8B to closing ¥255.5B, a decrease of ¥31.3B. Overall, cash decreased due to operating losses and share buybacks, but YoY improvement is significant. Conversion of short-term borrowings to long-term improved financial stability; correcting working capital (inventory normalization and faster collections) will be key to future cash generation.
Current revenue structure is generally recurring with limited one-off items. Against operating loss ¥-11.4B, financial income ¥0.9B and financial expenses ¥1.6B produced net financial expense ¥-0.6B (1.3% of revenue), and other income ¥0.0B / other expenses ¥0.1B summed to a minor ¥-0.1B. Business combination related expenses (intangible asset amortization) were ¥0.2B with limited impact on consolidated operating loss. Transition from ordinary loss ¥-12.2B to profit before tax ¥-12.0B aligned closely aside from equity-method loss ¥-0.0B, and extraordinary items were effectively absent. Corporate tax benefit ¥3.5B resulted from restrained derecognition of deferred tax assets and refunds of prior year provisional payments; net loss ¥-8.5B was partially offset by tax effects. Comprehensive income was ¥-8.5B, matching net loss; other comprehensive income was nil with no non-recurring FX translation or marketable securities valuation impacts. Operating CF ¥-9.5B was nearly equivalent to net loss ¥-8.5B, so profit-loss and cash divergence is small. However, working capital showed AR decrease +¥9.3B (improved collection not included in recurring revenue), inventory increase -¥4.4B and prepaid items -¥11.8B, increasing accruals. Overall, earnings quality is stable on an ordinary basis with few one-offs, but operating CF deficit indicates weak internal cash generation; correcting inventory/prepaid items and margin improvement will determine quality of cash conversion going forward.
Company full-year plan: Revenue ¥320.0B, Operating Income ¥46.0B, Net Income ¥30.0B, Dividend ¥0. Q1 results: Revenue ¥47.6B (progress 14.9%), operating loss ¥-11.4B (below plan), net loss ¥-8.5B (below plan), significantly under standard equal-quarter pacing (Q1 = 25%). Main reasons for sluggish revenue progress are assumed to be postponement of Drug Discovery milestone/license income and Q1 Radiopharmaceutical sales below plan. Despite gross margin improvement, operating profit remains negative in Q1 due to front-loaded R&D and losses in Drug Discovery; to achieve full-year profitability, Radiopharmaceutical margin improvement (from 1.8% upward) and multiple milestone recognitions in Drug Discovery are indispensable. To meet the full-year target, average quarterly revenue of approx. ¥91B and operating profit exceeding ¥2.0B per quarter from Q2 onward (or concentrated performance in later quarters) is needed; realization of large deals and accelerated cost reduction are prerequisites. Order backlog / contract liabilities (advance receipts) decreased to ¥7.5B (prior year ¥10.0B), a mildly weak leading indicator. No revision to full-year guidance was announced this quarter; however, given the slow Q1 start, confirmation of progress in Q2 is critical.
Dividend this period ¥0 (prior year ¥0). With continued operating losses, dividends were withheld and the company maintains a full-year dividend plan of ¥0. Meanwhile, treasury stock purchases of ¥10.0B were executed (prior year ¥9.6B), indicating some continuation of shareholder returns as part of capital policy. Free CF was ¥-12.7B (negative), so buybacks were financed from cash balance and borrowings. Payout Ratio is not meaningful under net loss, and Total Return Ratio is also not calculable under negative earnings. Cash balance ¥255.5B is ample, but sustainability of returns while operating CF remains negative is a concern. Resumption of dividends is likely conditioned on return to operating profitability and positive free cash flow. Continued treasury stock purchases signal intent to enhance per-share value, but strengthening business cash generation is key to sustaining return policy.
Concentration risk in Radiopharmaceuticals: Radiopharmaceuticals represent 85.9% of external sales; variability in demand for diagnostic and therapeutic products, disruption in radionuclide supply, regulatory changes, and reimbursement price revisions directly affect performance. Segment operating margin this period is 1.8%—extremely thin—so deteriorations in manufacturing yield or unsuccessful price negotiations pose high downside risk. Limited geographic/product diversification and single-business dependence increase financial volatility.
Continued losses and front-loaded investment risk in Drug Discovery: Drug Discovery segment has revenue ¥6.7B versus operating loss ¥-11.9B (margin -177.9%), with heavy front-loaded R&D spending ¥12.3B (25.8% of revenue). Clinical trial delays/failures, difficulties in partnership negotiations, or missed milestones could undermine plan assumptions and jeopardize the full-year operating income target ¥46.0B. Decrease in order backlog / contract liabilities (¥7.5B vs prior year ¥10.0B) is a weak leading indicator; realization of projects from Q2 onward is uncertain.
Working capital management and liquidity risk: Inventory ¥36.3B (prior year ¥31.9B, +13.8%) increased faster than revenue, with estimated inventory days ~119 and a lengthening trend. Risk of inventory obsolescence/valuation write-downs and cash tie-up is a concern. Operating CF remains ¥-9.5B and prepaid expenses increased -¥11.8B, accelerating cash outflows. Free CF ¥-12.7B indicates outflow; while cash balance ¥255.5B is ample, ongoing operating deficits and continued buybacks could erode liquidity over time. Short-term borrowings were largely converted to long-term (now ¥26.1B), improving maturity profile, but prolonged operating CF deficits would gradually consume financial flexibility.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | -23.9% | – | – |
| Net Profit Margin | -17.9% | – | – |
Median industry benchmark data are insufficient for robust comparison, but the company’s operating margin of -23.9% is considered a temporary level for an R&D-first, discovery-oriented company, and progress to profitability will be the inflection point for industry assessment.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth (YoY) | 12.6% | – | – |
Revenue growth of +12.6% is solid two-digit growth, but relative industry ranking requires median data. Market expansion in radiopharmaceuticals and progression of discovery partnerships support this growth.
※Source: Company aggregation
Gross margin improvement and operating leverage inflection: Gross margin improved to 42.6% (from 34.7%, +7.9pp), evidencing manufacturing efficiency and mix effects. Operating loss narrowed by 16.6%, and with top-line growth and fixed-cost absorption there is a visible roadmap toward profitability. Radiopharmaceutical margin improvement (currently 1.8%) and milestone recognition in Drug Discovery are the primary drivers of future profitability. Monitor quarterly trends in gross margin, SG&A ratio, and the extent to which operating leverage materializes.
Improved financial stability and capital allocation flexibility: Large reduction in short-term borrowings (¥170.4B → ¥26.1B) and conversion to long-term borrowings (¥137.3B) significantly reduced maturity mismatch risk; current ratio improved to 406%. Net cash approx. ¥92B and equity ratio 66.6% provide strong financial resilience, allowing continuation of R&D investment alongside buybacks. Although operating CF is negative, the YoY improvement (¥-98.3B → ¥-9.5B) suggests that with working capital correction and margin improvement, a full recovery in cash generation is feasible.
Uncertainty in achieving full-year plan and importance of Q2: Q1 revenue progress 14.9% and continued operating loss overshoots standard pacing by over 10pp. To achieve full-year operating income ¥46.0B, quarterly average operating income of over ¥20B is required in later quarters, contingent on multiple milestone recognitions in Drug Discovery and substantial margin improvement in Radiopharmaceuticals. Decline in order backlog / contract liabilities (¥7.5B vs prior year ¥10.0B) is a weak leading indicator; Q2 realization of projects and progress rates will be the trigger for re-evaluating full-year guidance.
This report is an AI-generated earnings analysis document created by analyzing XBRL financial statement data. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are reference information aggregated by the company from publicly disclosed financial statements. Investment decisions are your responsibility; please consult experts as needed before making investment decisions.